# Orchard Therapeutics

> British gene therapy company

**Wikidata**: [Q107364296](https://www.wikidata.org/wiki/Q107364296)  
**Source**: https://4ort.xyz/entity/orchard-therapeutics

## Summary
Orchard Therapeutics is a British gene therapy company that became a public company in 2015. It is listed on the Nasdaq stock exchange under the ticker symbol ORTX and operates within the pharmaceutical industry.

## Key Facts
*   Orchard Therapeutics is a public company, meaning its securities are traded on the open market.
*   The company was founded in 2015.
*   It is headquartered in the United Kingdom.
*   Its stock is traded on the Nasdaq exchange with the ticker symbol ORTX.
*   Orchard Therapeutics operates in the pharmaceutical industry, specifically focusing on gene therapy.
*   The company's revenue was $17,110,000 (United States dollar).
*   It employs approximately 180 people.
*   Its official website is https://www.orchard-tx.com, which is presented in English.
*   The company is registered in the European Union Transparency Register with the ID 181526639749-13.

## FAQs
**What is Orchard Therapeutics and what does it do?**
Orchard Therapeutics is a British company founded in 2015 that specializes in developing gene therapies. It is a public entity in the pharmaceutical sector, listed on the Nasdaq stock exchange.

**Where is Orchard Therapeutics based and where is it traded?**
The company is headquartered in the United Kingdom. Its shares are publicly traded on the Nasdaq stock market in the United States under the ticker symbol ORTX.

**How large is Orchard Therapeutics as an organization?**
As a public company, Orchard Therapeutics has disclosed a revenue of $17.11 million and employs a workforce of 180 people. It is registered for lobbying activities in the European Union.

## Why It Matters
Orchard Therapeutics represents a significant player in the advanced field of gene therapy, a branch of the pharmaceutical industry aimed at treating diseases at the genetic level. As a publicly traded company, it utilizes capital markets to fund research and development for potentially transformative medical treatments. Its existence and financial disclosures contribute to the broader ecosystem of biotechnology investment and innovation.

## Notable For
*   Being a publicly traded British company focused exclusively on gene therapy.
*   Its specific registration in the EU Transparency Register, indicating its engagement with European policy.
*   Operating as a substantial enterprise within its niche, with nearly 200 employees and multimillion-dollar revenue.

## Body

### Corporate Identity and Classification
Orchard Therapeutics is legally structured as a company and is specifically classified as a public company. This means it has offered its securities for sale to the general public, a process that provides capital for its operations. Its core business activity places it within the pharmaceutical industry.

### Founding and Global Presence
The company was established in 2015. It is headquartered in the United Kingdom but has a significant international presence, evidenced by its listing on the Nasdaq, a major American stock exchange. Its registration in the EU Transparency Register further confirms its activities within the European economic area.

### Financial and Operational Scale
As a public entity, Orchard Therapeutics discloses key financial metrics. Its revenue is reported as $17,110,000 (United States dollar). The company employs 180 people, indicating its size as a mid-scale organization within the biotech sector.

### Public Market Details
Orchard Therapeutics is listed on the Nasdaq stock exchange. Its ticker symbol, used for trading its shares, is ORTX. The company maintains an official website at https://www.orchard-tx.com, which is presented in the English language.

### Regulatory Registration
The company is formally recorded in the European Union Transparency Register under the identification number 181526639749-13. This register is for organizations engaged in activities aimed at influencing the policymaking and implementation processes of the EU institutions.

## References

1. [Source](https://www.lobbyfacts.eu/datacard/orchard-therapeutics?rid=181526639749-13)
2. [Source](https://www.dnb.com/business-directory/company-profiles.orchard_therapeutics_north_america.540a76156221fdef2b684a469102bc36.html)